Showing results (321-330 of 341) with videos related to
Sort By:
Pageof 35
Journal of Medical Genetics|December 7, 2016
A novel somatic mutation achieves partial rescue in a child with Hutchinson-Gilford progeria syndromeDaniel Z Bar, Martin F Arlt, Joan F Brazier, et al.Bioorganic & Medicinal Chemistry Letters|March 12, 2004
Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivativesJiabing Wang, Michael J Breslin, Paul J Coleman, et al.Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backboneDavid B Whitman, Ben C Askew, Le T Duong, et al.Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Non-peptide alpha(v)beta(3) antagonists: identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraintJames J Perkins, L T Duong, Carmen Fernandez-Metzler, et al.The Journal of Steroid Biochemistry and Molecular Biology|May 30, 2008
Agonist-like SERM effects on ERalpha-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterusAngela Scafonas, Alfred A Reszka, Donald B Kimmel, et al.Cell Reports|January 3, 2025
Anti-herpetic tau preserves neurons via the cGAS-STING-TBK1 pathway in Alzheimer's diseaseVanesa R Hyde, Chaoming Zhou, Juan R Fernandez, et al.Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Nonpeptide alpha V beta 3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivativeMichael J Breslin, Mark E Duggan, Wasyl Halczenko, et al.Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacementsKaren M Brashear, Cecilia A Hunt, Brian T Kucer, et al.Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimeticsPaul J Coleman, Ben C Askew, John H Hutchinson, et al.Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptideRobert S Meissner, James J Perkins, Le T Duong, et al.Pageof 35